Product category:
Pharmaceutical Processing News
News Release from: Ceram | Subject: Counterfeit drug detection
Edited by the Processingtalk Editorial
Team on 19 April 2006
CSMA in counterfeit drug detection
breakthrough
CSMA, the industry expert in materials analysis, has developed a method for detecting counterfeit drugs which could revolutionise detection practice in the pharmaceutical industry
CSMA, the industry expert in materials analysis based in Stoke-on-Trent, has developed a method for detecting counterfeit drugs which could revolutionise detection practice in the pharmaceutical industry The work, carried out in collaboration with Glaxo Smith Kline, was conducted in response to requests from the FDA (Food and Drug Administration) for major drug companies to do more to combat the growing problem of counterfeit drugs, which currently accounts for ten per cent of the global pharmaceuticals market
This article was originally published on Processingtalk on 31 Mar 2006 at 8.00am (UK)
Related stories
Ceram advice helps steer Midlands company
After seeking Ceram advice a Midlands Engineering company has not only experienced a GBP200,000 improvement in manufacturing output, but also employed eight new members of staff
CSMA materials analysis solves pharma QA problem
CSMA, materials analysis expert and subsidiary of Ceram, has helped solve a production crisis for a major global pharmaceutical manufacturer, preventing a potential income loss of up to US$100million
By using surface analysis techniques to examine ingredient content and dispersal at the extreme surface of a drug, CSMA has developed a method of detecting differences in manufacturing routes.
Drugs produced using manufacturing methods other than those employed by the original pharmaceutical companies can therefore be identified.
Although further development of the detection system is required, the research is already being hailed as a major breakthrough.
Rob Mitchell, who led the research programme at CSMA, comments: "The circulation of counterfeit drugs costs the pharmaceutical industry billions, both in terms of revenue loss and in developing programmes to help combat the problem.
"Add to this the fact that, at their crudest, counterfeit drugs may contain ingredients that are detrimental to the health of the patient, possibly even fatal, and it is clear to see how important this research is".
CSMA is a subsidiary of CERAM, the internationally renowned centre for materials and technology.
For further information on this research or on the range surface analysis techniques and services offered by CSMA, please contact Shaun Bainbridge. Request a free brochure from Ceram ...
• Ceram: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
